Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
O-25 BACTERIAL INFECTION ENHANCES THROMBIN GENERATION IN PATIENTS WITH CIRRHOSIS
Marina Pamponet Motta1, Elbio Antonio D’Antonio D’Amico2, Tania Rubia Flores da Rocha2, Beatriz Yurí Migita1, Juliana Medeiros Batista1, Caroline Marcondes Ferreira1, Flávio José Carrilho1, Alberto Queiroz Farias1
1 Department of Gastroenterology, University of Sao Paulo School of Medicine
2 Coagulation Laboratory, Division of Hematology, University of Sao Paulo School of Medicine

Introduction and Aims: Current concept of coagulopathy in cirrhosis indicates that there is a rebalancing of homeostasis with plasma hypercoagulability. Bacterial infection can promote releases of endotheal heparinoids. However, the effect of this condition on the thrombin generation is unknown. Our aim was to assess the effect of bacterial infection on thrombin generation in cirrhosis.

Methods: 38 patients with cirrhosis and bacterial infection (infected group) were evaluated within 24 hours after start antibiotic and at least 5 days after infection resolution. 28 patients with decompensated cirrhosis and not infected (not infected group) were also enrolled and reevaluated, without any intervention between evaluation times. Primary endpoint was the effect of bacterial infection on thrombin generation (TG) parameter ETP with TM (ETP TM). TM is a protein C activator added to mimic in vivo conditions. ROTEM assays, INTEM and HEPTEM (heparinase modified), was performed to evaluate the endogenous heparinoid effects. Protein C (PC) and antithrombin (AT) assays were performed. All results were compared within each group between evaluation times.

Results: ETP TM values in infected cirrhotics were significantly higher than after resolution of infection (from 1145.4 ± 360.7 min/L to 958.1 ± 254.8 min/L p=0.005) - figure 1. A heparinoid effect was found only in infected cirrhotics, with CTINTEM duration significantly longer than CTHEPTEM (p=0.004). This effect disappeared after resolution of infection (p=0.75). PC and AT deficiencies were significantly more severe in infected patients (p<0.1). INR/TP, aPTT was worsen at active infection (p<0.1). None of these parameters exhibited a significant difference between inclusion and revaluation times in not infected group.

Conclusion: patients with cirrhosis exhibits significant higher amount of TG during bacterial infection and it is associated with reduction of PC and AT levels. Despite the endogenous heparinoid effect during infection in cirrhosis, plasma hypercoagulability is preserved and cannot be assessed by conventional coagulation tests.

O-26 ASPARTATE AMINOTRANSFERASE, AGE AND D-DIMER IN COVID-19 PATIENTS: A USEFUL PROGNOSTIC MODEL
Fátima Higuera-de la Tijera1,2, Alfredo Servín-Gamaño1,2, Daniel Reyes-Herrera1,3, Angelia Flores-López1,2, Enrique J.A. Robiou-Vivero1,3, Felipe Martínez-Rivera1,3, Víctor Galindo-Hernández1,3, Catalina Casillas-Suárez1,2, Oscar Chapa-Azuela1,5, Alfonso Chávez-Morales1,6, Víctor Hugo Rosales-Salyano1,3, Billy Jiménez-Bobadilla1,7
1 Multidisciplinary Team for the Attention and Care of Patients with COVID-19, Hospital General de México Dr. Eduardo Liceaga; Mexico City, Mexico
2 Gastroenterology and Hepatology Department, Hospital General de México Dr. Eduardo Liceaga; Mexico City, Mexico
3 Internal Medicine Department, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
4 Pneumology Department, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
5 General Surgery Department, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
6 Intensive Care Unit, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
7 Colorectal Surgery Department, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
8 Infectious Disease Department, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
9 Gynecology Department, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico

Introduction: Some patients with SARS-CoV-2 infection develop severe disease (SARS); however, the factors associated with severity are not yet fully understood. Some reports indicate that liver injury may be a poor prognostic factor.

Aim: To identify the biochemical factors related to the development of SARS with mechanical ventilation (MV) requirement in patients with SARS-CoV-2 and COVID-19.

Methods Type of study: Observational. Cohort study.

Procedure: Data from COVID-19 patients were collected at admission time to a tertiary care center. Differential factors were identified between seriously ill SARS+MV patients versus stable patients without MV. Transformation to the natural logarithm of significant variables was performed and multiple linear regression was applied, then a predictive model of severity called AAD (Age-AST-D dimer) was constructed.

Results: 166 patients were included, 114(68.7%) men, mean age 50.6±13.3 years-old, 27(16.3%) developed SARS+MV. In the comparative analysis between those with SARS+MV versus stable patients without MV we found significant raises of ALT (225.4±341.2 vs. 41.3±41.1; P=0.003), AST 325.3±382.4 vs. 52.8±47.1; P=0.001), LDH (764.6±401.9 vs. 461.0±185.6; P=0.001), D dimer (7765±9109 vs. 1871±4146; P=0.003), age (58.6±12.7 vs. 49.1±12.8; P=0.001). The results of the regression are shown in the Table, where model 3 was the one that best explained the development of SARS+MV; with these variables was constructed the model called AAD, where: [AAD= 3.896 + ln(age)x-0.218 + ln(ALT) x-0.185 + ln(DD)x0.070], where a value ≤ 2.75 had sensitivity=0.797 and 1-specificity= 0.391, AUROC=0.74 (95%CI: 0.62-0.86; P<0.0001), to predict the risk of developing SARS+MV (OR=5.8, 95%CI: 2.2-15.4; P=0.001).

Conclusions: Elevation of AST (probable marker of liver damage) is an important predictor of progression to SARS, together with elevation of D-dimer and age early (at admission) and efficiently predict which patients will potentially require MV.
The overall genotype distribution was as follows: F 46.8%, D 26.1%, A 25.2%, and B 0.7% and C 0.7%. While no impact of the HBV genotype significantly among genotypes (p < 0.001). The highest HBsAg levels were observed in genotype F (4.9±0.6 Log_{10}IU/ml) and genotype D (2.4±0.9 Log_{10}IU/ml). In genotype A and F, qHBsAg <3.0 Log_{10}IU/ml were only observed in 10.7% and 11.5% respectively.

Regardless of the HBV genotype, spontaneous clearance of HBsAg was observed in 17 cases. Of these, 12 patients presented qHBsAg <100 IU/ml one year before clearance. Despite, 101 (71.6%) patients showed qHBsAg >3.0 Log_{10}IU/ml, no cases of advanced liver disease or hepatocellular carcinoma were observed at the end of follow-up.

Conclusions: This study provides new insights into the impact of HBV genotypes on serum HBsAg levels, emphasizing the need to implement genotype-specific cut-off to achieve diagnostic certainty in the identification of HBeAg-negative chronic infection and the risk of liver disease progression, particularly in infections with genotypes A and F. Moreover, HBsAg serum levels can become a reliable biomarker to predict HBsAg clearance.

https://doi.org/10.1016/j.aohep.2021.100514

O-28 DRUG-INDUCED LIVER INJURY IN LATINAMERICA: First ten years’ experience of the ongoing LATINIDILI Network

Fernando Bessone1, Nelia Hernandez2, Raymundo Parana1, Manuel Mendizabal4, Adriana Sanchez2, Vinicius Nunes3, Ezequiel Ridruejo1, Daniela Schiodi2, Genario Santos3, Eduardo Fassio3, Schinoni Maria L.3, Hugo Tanno1, Martin Tagle7, Pedro Montes8, Marco Arrese9, Nahum Mendez-Sanchez10, Javier Brahmi11, Marcos Girala12, Isabel Lizarzabal M.13, Edgardo Menguil3, Enrique Carrera14, Fernando Contreras15, Immaculada Medina-Caliz16, Mercedes Robles-Díaz16, Aida Ortega-Alonso16, Miren García-Cortes16, Ismael Alvarez-Alvarez16, Hao Niu16, Elvira Bonilla16, Isabel Lucena M.16, Andrade Raul J.16

1 Hospital Provincial del Centenario, University of Rosario School of Medicine, Rosario, Argentina
2 Clínica de Gastroenterología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay
3 Hospital Universitario Prof. Edgard Santos-UFBA, Salvador, Brazil
4 Hospital Universitario Austral, Buenos Aires, Argentina
5 Centro de Educación Médica e Investigaciones Clinicas, Buenos Aires, Argentina
6 Hospital Alejandro Posadas, Buenos Aires, Argentina
7 Clínica Anglo Americana, Lima, Perú
8 Hospital Nacional Daniel Alcides Carrion, Callao, Perú
9 Departamento de Gastroenterología. Facultad de Medicina Pontificia Universidad Católica de Chile, Chile
10 Fundación Clínica Médica Sur, Mexico City, Mexico
11 Hospital Clínico Universitario de Chile, Chile
12 Hospital de Clínicas, Asunción del Paraguay, Paraguay
13 Hospital Universitario de Maracaibo, Maracaibo, Venezuela
14 Hospital de Especialidades Eugenio Espejo, Quito, Ecuador
15 Universidad Nacional Pedro Henriquez, Santo Domingo, República Dominicana
16 Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de la Victoria,